Increasing Transparency in Generic Drug Applications Act

Bill 119 s 1302, also known as the "Increased Transparency in Generic Drug Applications Act," aims to improve transparency in the generic drug application process. The bill requires the Food and Drug Administration (FDA) to publish information about generic drug applications on their website, including the status of the application and any delays in the approval process.

Additionally, the bill requires the FDA to provide more information about the reasons for any delays in the approval process, such as the need for additional testing or data. This information will help ensure that generic drugs are approved in a timely manner and will increase competition in the pharmaceutical market, ultimately leading to lower drug prices for consumers.

Overall, Bill 119 s 1302 seeks to increase transparency and accountability in the generic drug approval process, ultimately benefiting consumers by ensuring timely approval of generic drugs and promoting competition in the pharmaceutical market.